Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CfDNA in Hereditary And High-risk Malignancies (CHARM) 2: Evaluating the Performance of a cfDNA Blood Test for Early Cancer Detection

NCT06726642 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT06726642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06726642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CfDNA in Hereditary And High-risk Malignancies (CHARM) 2: Evaluating the Performance of a cfDNA Blood Test for Early Cancer Detection
Lead sponsor
University Health Network, Toronto
Phase
Observational
Overall status
Recruiting
Start date
April 19, 2024
Completion date
December 31, 2031
Enrollment
1,000 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary cancer syndrome